{"id":639,"date":"2026-09-29T14:52:39","date_gmt":"2026-09-29T09:22:39","guid":{"rendered":"https:\/\/www.wittytrades.com\/market-news\/mankind-share-price-today-2026-09-29\/"},"modified":"2026-10-05T20:51:39","modified_gmt":"2026-10-05T15:21:39","slug":"mankind-share-price-today-2026-09-29","status":"publish","type":"post","link":"https:\/\/www.wittytrades.com\/market-news\/mankind-share-price-today-2026-09-29\/","title":{"rendered":"Mankind Pharma Share Price Rises Today: Why MANKIND Stock is Moving | 29 September 2026"},"content":{"rendered":"<style id=\"wt-article-style-v4\">:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) { color:#30475c; font-size:16px; line-height:1.65; min-width:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) *, :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) *::before, :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) *::after { box-sizing:border-box; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-copy { font-size:16px !important; line-height:1.65 !important; margin:0 0 12px !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-prose .wt-copy { margin-bottom:15px !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-market-date { font-size:13px !important; line-height:1.55; color:#566b80; background:#f2f6f9; border:1px solid #dde6ec; border-left:4px solid #2e7db2; border-radius:6px; padding:8px 11px; margin:0 0 12px !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip { display:grid; grid-template-columns:repeat(6,minmax(0,1fr)); gap:7px; margin:8px 0 16px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div { padding:10px !important; min-width:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div > div:first-child { font-size:11px !important; line-height:1.45; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div > div:last-child { font-size:14px !important; line-height:1.5; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card { padding:14px 16px; min-width:0; overflow-wrap:anywhere; margin:14px 0 18px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card-title { font-size:16px; font-weight:800; line-height:1.45; color:#17324d; margin-bottom:6px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card-date { font-size:13px; line-height:1.5; color:#566b80; margin-bottom:9px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card-body { font-size:16px; line-height:1.6; color:#34495d; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card-body .wt-copy:last-child { margin-bottom:0 !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid { display:grid; grid-template-columns:repeat(2,minmax(0,1fr)); gap:12px; margin:12px 0 18px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid > .wt-card { margin:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid > :only-child { grid-column:1 \/ -1; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-metrics { grid-template-columns:repeat(3,minmax(0,1fr)); margin:10px 0 12px; gap:10px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-metric { background:#fff; border:1px solid #e1e8ef; border-radius:8px; padding:10px 12px; min-width:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-label { display:block; font-size:12px; font-weight:700; color:#566b80; line-height:1.5; margin-bottom:3px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-value { font-size:18px; font-weight:800; line-height:1.45; color:#17324d; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-note { display:block; font-size:13px; color:#566b80; line-height:1.55; margin-top:4px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-source-note { margin:9px 0 4px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-source { display:inline-block; font-size:13px; line-height:1.5; margin-top:6px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row { display:grid; grid-template-columns:2fr 1fr 1.2fr 1.2fr; gap:14px; padding:12px 0; border-bottom:1px solid #c9dbef; align-items:start; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row:last-of-type { border-bottom:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row strong { font-size:15px; line-height:1.5; display:block; color:#17324d; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row > div { min-width:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds { grid-template-columns:repeat(3,minmax(0,1fr)); margin:12px 0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds .wt-card { padding:12px; background:#fff !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds .wt-card-title { font-size:14px; font-weight:700; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds .wt-card-body { font-size:14px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-brokerage { grid-template-columns:1fr; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-broker-facts { display:flex; flex-wrap:wrap; gap:14px 28px; margin:7px 0 12px; padding-bottom:10px; border-bottom:1px solid #cbd8ea; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-broker-facts strong { font-size:16px; color:#17324d; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-list { font-size:16px !important; line-height:1.65; margin:0 0 12px; padding-left:20px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-list li { margin-bottom:6px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-takeaways .wt-card { background:#f7fbff !important; border-color:#cfe1f2 !important; border-left-color:#2e7db2 !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-takeaways .wt-card-title { color:#1f4d70; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-takeaways .wt-list { margin-bottom:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-likely-reason .wt-card { background:#f5fbfd !important; border-color:#c9d9e7 !important; border-left:5px solid #1f7b92 !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-likely-reason .wt-card-title { color:#174c5d; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-likely-reason .wt-card-body > strong { display:block; margin-bottom:6px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta { padding:18px 19px; margin:22px 0; border-radius:13px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-title { font-size:19px; font-weight:800; line-height:1.4; margin-bottom:7px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-yellow { background:linear-gradient(135deg,#ffe873,#ffd64a); border:1px solid #e3b600; box-shadow:0 8px 18px rgba(59,48,0,.09); }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-yellow .wt-cta-title { color:#10233f !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-yellow .wt-cta-copy { color:#27364b !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-dark { background:#10233f; box-shadow:0 9px 22px rgba(16,35,63,.18); }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-dark .wt-cta-title { color:#fff !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-dark .wt-cta-copy { color:#dce6f1 !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-copy { font-size:16px !important; line-height:1.6; margin:0 0 12px !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-button { display:inline-block; background:#10233f; color:#fff !important; padding:10px 17px; border-radius:7px; text-decoration:none !important; font-size:15px; font-weight:800; line-height:1.5; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-dark .wt-cta-button { background:#ffe36e; color:#10233f !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-faq h3 { color:#173b58 !important; font-size:17px !important; line-height:1.45; margin:18px 0 6px !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) > p:last-child { font-size:13px; line-height:1.55; color:#606b78; border-top:1px solid #e1e7ef; padding-top:13px; margin-top:16px; }\n@media (max-width:960px) {\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip { grid-template-columns:repeat(3,minmax(0,1fr)); }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row { grid-template-columns:1.7fr 1fr 1.2fr 1.2fr; gap:10px; }\n}\n@media (max-width:650px) {\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid { grid-template-columns:1fr; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-metrics { grid-template-columns:repeat(2,minmax(0,1fr)); }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card { padding:14px; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row { grid-template-columns:repeat(2,minmax(0,1fr)); gap:10px 14px; padding:12px 0; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-person, :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row > div:last-child { grid-column:1 \/ -1; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta { padding:17px 15px; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-title { font-size:18px; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div { padding:9px !important; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds .wt-card-title, :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds .wt-card-body { font-size:15px; }\n}\n@media (max-width:420px) {\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip { grid-template-columns:repeat(2,minmax(0,1fr)); }\n}<\/p>\n<p>:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div {border:1px solid #dde6ee;border-radius:8px;background:#f9fbfd;}\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div > div:last-child {font-weight:800;color:#17324d;}\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) h2 {font-size:24px !important;line-height:1.35 !important;margin:28px 0 14px !important;color:#173b58;}\n<\/style>\n<div class=\"wt-article-v4\" data-article-version=\"4\">\n<p class=\"wt-market-date\"><strong>NSE: MANKIND<\/strong> \u00b7 29 September 2026 \u00b7 Dated market coverage<\/p>\n<div class=\"wt-price-strip\">\n<div>\n<div>Price<\/div>\n<div>\u20b92,545.00<\/div>\n<\/div>\n<div>\n<div>Change<\/div>\n<div>+4.49%<\/div>\n<\/div>\n<div>\n<div>High \/ Low<\/div>\n<div>\u20b92,557.60 \/ \u20b92,440.40<\/div>\n<\/div>\n<div>\n<div>Prev. Close<\/div>\n<div>\u20b92,435.60<\/div>\n<\/div>\n<div>\n<div>Volume<\/div>\n<div>1,967,833<\/div>\n<\/div>\n<div>\n<div>Price as of<\/div>\n<div>29 Sep 2026 \u2022 03:15 PM IST<\/div>\n<\/div>\n<\/div>\n<div style=\"background:#f7fbff;border:1px solid #cfe1f2;border-left:5px solid #2e7db2;border-radius:10px;padding:15px 17px;margin:14px 0 18px;\" class=\"wt-card\">\n<div style=\"font-weight:900;color:#1f4d70;margin-bottom:7px;\" class=\"wt-card-title\">Key Takeaways<\/div>\n<ul style=\"margin:0;padding-left:18px;\">\n<li>The stock is +4.49% at \u20b92,545.00.<\/li>\n<li><strong>Likely reason:<\/strong>Stock-specific buying and volume surge <\/li>\n<li>Approximate traded value is<strong>\u20b9500.81 crore<\/strong>. <\/li>\n<li>It is -3.67% from its 52-week high and +33.27% from its 52-week low.<\/li>\n<li>The stock is being compared with<strong>Nifty Pharma<\/strong>alongside the Nifty 50. <\/li>\n<\/ul><\/div>\n<h2>Why Is Mankind Pharma Share Price Rising Today?<\/h2>\n<p class=\"wt-copy\">Latest NSE EOD report: 2026-09-29. Today&#8217;s Volume: 1,967,833; 5-Day Avg. Volume: 699,166; 20-Day Avg. Volume: 472,398; Volume vs 20-Day Avg.: 4.17x; Delivery Quantity: 697,782; Delivery %: 35.35%; Number of Trades: 84,454.<\/p>\n<div class=\"wt-prose\">\n<p class=\"wt-copy\">Mankind Pharma shares advanced notably in today&#8217;s session, gaining 4.49% to close at \u20b92,545.00. The stock opened at \u20b92,440.40 and touched an intraday high of \u20b92,557.60, operating near the upper bound of its daily price band. Trading activity spiked significantly, with volume surging to 2.81 times its 5-day average and 4.17 times its 20-day average, accompanied by a healthy delivery percentage of 35.35%.<\/p>\n<p class=\"wt-copy\">In relative terms, Mankind Pharma outperformed the broader market and outpaced its sectoral benchmark. While the benchmark Nifty index slipped by 0.28%, the Nifty Pharma sector gained a modest 0.64%, reflecting strong buying interest centered specifically on Mankind against a flat-to-negative broader market backdrop.<\/p>\n<p class=\"wt-copy\">On the corporate and news front, the company recently announced the resignation of the statutory auditors of its material wholly-owned subsidiary, Bharat Serums and Vaccines Limited, following earlier board consent for its voluntary liquidation and integration into the parent company. While these administrative restructuring updates provide backdrop context, today&#8217;s sharp price momentum and high trading volume appear primarily driven by strong stock-specific accumulation and buying interest.<\/p>\n<\/div>\n<div style=\"border:1px solid #c9d9e7;border-left:5px solid #1f7b92;border-radius:10px;background:#f5fbfd;padding:16px 18px;margin:16px 0 22px;\" class=\"wt-card\">\n<div style=\"gap:10px;align-items:center;flex-wrap:wrap;margin-bottom:7px;\" class=\"wt-card-title\">\n<div style=\"font-weight:900;color:#174c5d;\">Likely Reason for Today&#8217;s Move<\/div>\n<p> <span style=\"background:#fff1cf;color:#8a6116;padding:3px 8px;border-radius:999px;font-weight:900;text-transform:uppercase;\">medium confidence<\/span> <\/div>\n<div style=\"font-weight:850;color:#20384a;margin-bottom:7px;\">Stock-specific buying and volume surge<\/div>\n<div style=\"\">The stock rallied 4.49% on significantly elevated trading volume (over 4x its 20-day average), outperforming both the broader Nifty and Nifty Pharma indices. While recent corporate restructuring updates regarding its subsidiary provide context, the sharp price movement reflects strong underlying buying interest.<\/div>\n<ul style=\"margin:10px 0 0;padding-left:18px;\">\n<li>Intraday gain of 4.49% with price closing near the day&#8217;s high of \u20b92,557.60<\/li>\n<li>Volume surged to 4.17 times the 20-day average<\/li>\n<li>Outperformed Nifty&#8217;s decline of 0.28% and Nifty Pharma&#8217;s gain of 0.64%<\/li>\n<\/ul><\/div>\n<aside class=\"wt-cta wt-cta-yellow\">\n<div class=\"wt-cta-title\">Research the Market \u2014 Not Just the Headline<\/div>\n<p class=\"wt-cta-copy\">Explore WittyTrades research across market segments.<\/p>\n<p><a class=\"wt-cta-button\" href=\"https:\/\/www.wittytrades.com\/Segments.html\">Explore WittyTrades Research \u2192<\/a><\/aside>\n<h2>Ownership &amp; Transaction Activity<\/h2>\n<div class=\"wt-grid\" style=\"gap:16px;margin:14px 0 22px;width:100%;box-sizing:border-box;\">\n<div style=\"background:#fff5df;border:1px solid #ecd39e;border-left:5px solid #cc922c;border-radius:10px;padding:17px 19px;box-sizing:border-box;min-width:0;\" class=\"wt-card wt-card\">\n<div style=\"margin:0 0 10px;color:#8c6318;\" class=\"wt-card-title\">Promoter Pledge \/ Encumbrance<\/div>\n<p style=\"margin:0;\" class=\"wt-copy\">Completion of Realignment of Security Cover in respect of Non-ConvertibleDebentures and Consequent Release of Pledged Shares of Bharat Serums andVaccines Limited<\/p>\n<p style=\"margin:10px 0 0;color:#7b673d;\" class=\"wt-copy\">Source: NSE corporate filing<\/p>\n<\/p><\/div>\n<div style=\"background:#f5f8fb;border:1px solid #d5e0ea;border-left:5px solid #6a849c;border-radius:10px;padding:17px 19px;box-sizing:border-box;min-width:0;\" class=\"wt-card wt-card\">\n<div style=\"margin:0 0 10px;color:#405d76;\" class=\"wt-card-title\">Recent Ownership \/ Shareholding Disclosure<\/div>\n<div style=\"\">Promoters and promoter group confirmed that no encumbrances or pledges were created on their shareholdings during the financial year ended March 31, 2026, complying with SEBI takeover regulations.<\/div>\n<ul style=\"margin:10px 0 0;padding-left:18px;\">\n<li>Promoter group submitted compliance disclosures under Regulation 31(4) of SEBI SAST Regulations confirming zero encumbrances for FY ending March 31, 2026.<\/li>\n<li>Ramesh Juneja, Rajeev Juneja, and Sheetal Arora are listed among the key promoter and promoter group entities.<\/li>\n<\/ul>\n<p style=\"margin:10px 0 0;color:#647789;\" class=\"wt-copy\">Source: NSE corporate disclosure. Only factual ownership\/shareholding details extracted from the filing are shown.<\/p>\n<\/p><\/div>\n<\/p><\/div>\n<div class=\"witty-insight\">\n<h3>WittyTrades Data Insight<\/h3>\n<p class=\"wt-copy\"><strong>Price Position:<\/strong>The stock is near the upper end of the day&#8217;s trading range. <\/p>\n<p class=\"wt-copy\"><strong>Move From Open:<\/strong>+4.29%. <\/p>\n<p class=\"wt-copy\"><strong>Intraday Range:<\/strong>4.81% of the previous close. <\/p>\n<p class=\"wt-copy\"><strong>5-Day Performance:<\/strong>+2.62%; <strong>20-Day Performance:<\/strong>+8.00%. <\/p>\n<\/p><\/div>\n<aside class=\"wt-cta wt-cta-yellow\">\n<div class=\"wt-cta-title\">Research the Market \u2014 Not Just the Headline<\/div>\n<p class=\"wt-cta-copy\">Explore WittyTrades research across market segments.<\/p>\n<p><a class=\"wt-cta-button\" href=\"https:\/\/www.wittytrades.com\/Segments.html\">Explore WittyTrades Research \u2192<\/a><\/aside>\n<h2>Latest Company Developments<\/h2>\n<div style=\"background:#fbfcfe;border:1px solid #e3e9f0;border-radius:12px;padding:14px;margin:12px 0 24px;width:100%;box-sizing:border-box;\" class=\"wt-card\">\n<div style=\"border:1px solid #dce5eb;border-radius:10px;padding:15px 16px;background:#ffffff;margin-bottom:12px;\">\n<div style=\"font-weight:800;color:#17324d;margin-bottom:4px;\">Resignation of Subsidiary Statutory Auditors<\/div>\n<div style=\"color:#708090;margin-bottom:6px;\">28-Sep-2026<\/div>\n<div style=\"\">Mankind Pharma notified the exchanges regarding the resignation of the statutory auditors of its material wholly-owned subsidiary, Bharat Serums and Vaccines Limited. This follows the board&#8217;s earlier decision to pursue the voluntary liquidation and complete integration of the subsidiary into the parent company.<\/div>\n<div style=\"margin-top:8px;color:#4f5f6e;\"><strong>Why it matters:<\/strong>Auditor changes in material subsidiaries require monitoring for corporate governance continuity during corporate restructuring. <\/div>\n<\/p><\/div>\n<div style=\"border:1px solid #dce5eb;border-radius:10px;padding:15px 16px;background:#ffffff;margin-bottom:12px;\">\n<div style=\"font-weight:800;color:#17324d;margin-bottom:4px;\">Exclusive In-Licensing Agreement for Insulins<\/div>\n<div style=\"color:#708090;margin-bottom:6px;\">20-Aug-2026<\/div>\n<div style=\"\">The company entered into an exclusive in-licensing agreement for Insulin Degludec and Insulin Degludec plus Aspart combination products for the Indian market. This expands Mankind&#8217;s specialized anti-diabetic and chronic care product portfolio.<\/div>\n<div style=\"margin-top:8px;color:#4f5f6e;\"><strong>Why it matters:<\/strong>Strengthens the company&#8217;s foothold in the high-growth chronic therapeutic segment and expands its branded formulation pipeline. <\/div>\n<\/p><\/div>\n<div style=\"border:1px solid #dce5eb;border-radius:10px;padding:15px 16px;background:#ffffff;margin-bottom:12px;\">\n<div style=\"font-weight:800;color:#17324d;margin-bottom:4px;\">Approval for Voluntary Liquidation of Subsidiary<\/div>\n<div style=\"color:#708090;margin-bottom:6px;\">26-Aug-2026<\/div>\n<div style=\"\">The board of directors granted formal consent for the integration of Bharat Serums and Vaccines Limited, a material wholly-owned subsidiary, into Mankind Pharma through a voluntary liquidation process.<\/div>\n<div style=\"margin-top:8px;color:#4f5f6e;\"><strong>Why it matters:<\/strong>Streamlines corporate structure and operational synergies by absorbing a major acquired entity directly into the parent company. <\/div>\n<\/p><\/div>\n<\/p><\/div>\n<div class=\"wt-grid\" style=\"gap:16px;margin:22px 0 24px;width:100%;box-sizing:border-box;\">\n<div style=\"border:1px solid #c8dfd9;border-radius:12px;padding:17px;background:#f0faf7;box-sizing:border-box;min-width:0;\" class=\"wt-card\"><\/div>\n<div style=\"border:1px solid #d4cdeb;border-radius:12px;padding:17px;background:#f7f3ff;box-sizing:border-box;min-width:0;\" class=\"wt-card\"><\/div>\n<\/p><\/div>\n<h2>What Should Traders and Investors Watch Next?<\/h2>\n<ul>\n<li>Progress and regulatory approvals regarding the voluntary liquidation and integration of Bharat Serums and Vaccines Limited<\/li>\n<li>Commercialization updates on the newly in-licensed insulin products in the anti-diabetic segment<\/li>\n<li>Sustained delivery volumes and price stability above key moving averages<\/li>\n<li>Upcoming financial results and management commentary on chronic therapy margins<\/li>\n<\/ul>\n<aside class=\"wt-cta wt-cta-yellow\">\n<div class=\"wt-cta-title\">Research the Market \u2014 Not Just the Headline<\/div>\n<p class=\"wt-cta-copy\">Explore WittyTrades research across market segments.<\/p>\n<p><a class=\"wt-cta-button\" href=\"https:\/\/www.wittytrades.com\/Segments.html\">Explore WittyTrades Research \u2192<\/a><\/aside>\n<p style=\"background:#f8fafc;border:1px solid #dce5eb;border-left:4px solid #6b7d90;border-radius:9px;padding:14px 16px;\" class=\"wt-copy\"><strong>Catalyst note:<\/strong>No single same-day catalyst was officially announced to directly trigger today&#8217;s surge, which appears driven by strong institutional or retail accumulation and volume expansion. <\/p>\n<h2>Frequently Asked Questions<\/h2>\n<h3>What is the likely reason for today&#8217;s move?<\/h3>\n<p class=\"wt-copy\">The stock rallied 4.49% on significantly elevated trading volume (over 4x its 20-day average), outperforming both the broader Nifty and Nifty Pharma indices. While recent corporate restructuring updates regarding its subsidiary provide context, the sharp price movement reflects strong underlying buying interest.<\/p>\n<h3>Is trading volume elevated?<\/h3>\n<p class=\"wt-copy\">Today&#8217;s volume is 1,967,833. The latest 20-day average available is 472,398, equivalent to about 4.17x of the recent average.<\/p>\n<h3>Before acting on this stock<\/h3>\n<p class=\"wt-copy\">Consult your own investment adviser before acting on any security. If you are interested in stock research or other available research categories, review the<a href=\"https:\/\/www.wittytrades.com\/Segments.html\"><strong>WittyTrades subscription plans and research segments<\/strong><\/a>. <\/p>\n<div class=\"witty-related\"><\/div>\n<p><strong>Article by:<\/strong><a href=\"https:\/\/www.wittytrades.com\/About_Us.html\">WittyTrades Research Desk<\/a><\/p>\n<div class=\"witty-disclaimer\"><strong>Disclaimer:<\/strong>Investments in securities markets are subject to market risks. Read all related documents carefully before investing. Registration granted by SEBI, membership of a supervisory body and certification from NISM do not guarantee performance of the intermediary or provide any assurance of returns to investors. This article is intended for informational and educational purposes and should not be treated as personalised investment advice or a recommendation to buy, sell or hold any security. Market data may be delayed and readers should independently verify current prices and disclosures before taking investment decisions. <\/div>\n<h2>Other Dated Coverage<\/h2>\n<ul class=\"wt-list\">\n<li><a href=\"https:\/\/www.wittytrades.com\/market-news\/mankind-share-price-today-2026-10-05\/\">Why Mankind Pharma Shares Fell 2.21% Today: Sector Weakness &amp; Context \u2014 5 October 2026<\/a><\/li>\n<li><a href=\"https:\/\/www.wittytrades.com\/market-news\/mankind-share-price-today-2026-10-01\/\">Why Mankind Pharma Shares Are Down 2.4% Today \u2014 1 October 2026<\/a><\/li>\n<li><a href=\"https:\/\/www.wittytrades.com\/market-news\/mankind-share-price-today-2026-09-30\/\">Why Mankind Pharma Shares Fell 1.6% Today: Sector Trends \u2014 30 September 2026<\/a><\/li>\n<\/ul>\n<p><a href=\"https:\/\/www.wittytrades.com\/market-news\/tag\/mankind\/\">More Mankind Pharma news and dated analysis \u2192<\/a><\/p>\n<\/div>\n<p><script type=\"application\/ld+json\">{\"@context\": \"https:\/\/schema.org\", \"@type\": \"NewsArticle\", \"@id\": \"https:\/\/www.wittytrades.com\/market-news\/mankind-share-price-today-2026-09-29\/#article\", \"mainEntityOfPage\": {\"@type\": \"WebPage\", \"@id\": \"https:\/\/www.wittytrades.com\/market-news\/mankind-share-price-today-2026-09-29\/\"}, \"headline\": \"Mankind Pharma Share Price Rises Today: Why MANKIND Stock is Moving | 29 September 2026\", \"description\": \"Mankind Pharma shares jumped 4.49% on heavy trading volume. Read our analysis on the price action, relative sector performance, and recent developments.\", \"datePublished\": \"2026-09-29T09:22:39Z\", \"dateModified\": \"2026-10-05T14:43:53.354897+00:00\", \"author\": {\"@type\": \"Organization\", \"name\": \"WittyTrades Research Desk\", \"url\": \"https:\/\/www.wittytrades.com\/About_Us.html\"}, \"publisher\": {\"@type\": \"Organization\", \"name\": \"WittyTrades\", \"url\": \"https:\/\/www.wittytrades.com\/\"}, \"inLanguage\": \"en-IN\", \"image\": [\"https:\/\/www.wittytrades.com\/market-news\/wp-content\/uploads\/2026\/10\/mankind-company-news-2026-09-29.jpg\"]}<\/script><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Mankind Pharma shares jumped 4.49% on heavy trading volume. Read our analysis on the price action, relative sector performance, and recent developments.<\/p>\n","protected":false},"author":1,"featured_media":3357,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"_witty_seo_title":"Mankind Pharma Share Price Rises Today: Why MANKIND Stock is Moving | 29 September 2026","_witty_meta_description":"Mankind Pharma shares jumped 4.49% on heavy trading volume. Read our analysis on the price action, relative sector performance, and recent developments.","_witty_primary_phrase":"Mankind Pharma share price 2026-09-29","_witty_reason_label":"Stock-specific buying and volume surge","_witty_reason_confidence":"medium","footnotes":"","_yoast_wpseo_title":"","_yoast_wpseo_metadesc":"","_yoast_wpseo_focuskw":"","rank_math_title":"","rank_math_description":"","rank_math_focus_keyword":"","_aioseop_title":"","_aioseop_description":""},"categories":[3,4],"tags":[32],"class_list":["post-639","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-market-movers","category-stocks-in-news","tag-mankind"],"_links":{"self":[{"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/posts\/639","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/comments?post=639"}],"version-history":[{"count":3,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/posts\/639\/revisions"}],"predecessor-version":[{"id":3359,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/posts\/639\/revisions\/3359"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/media\/3357"}],"wp:attachment":[{"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/media?parent=639"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/categories?post=639"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/tags?post=639"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}